Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology

International Journal of Cancer

Volumn 137, Issue 1, 2015, Pages 193-203

  Thomsen, Louise T ^a   Frederiksen, Kirsten ^a   Munk, Christian ^a   Junge, Jette ^b   Iftner, Thomas ^c   Kjaer, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

cervical cancer; high grade cervical intraepithelial neoplasia; HPV genotypes; HPV viral load; long term risk

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; MAJOR CLINICAL STUDY; NONHUMAN; ONSET AGE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TREND STUDY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VERY ELDERLY; VIRUS LOAD; VIRUS TYPING; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; DENMARK; EARLY DIAGNOSIS; GENETICS; GENOTYPE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

VIRUS DNA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DENMARK; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL LOAD; YOUNG ADULT;

EID: 84930415323     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29374     Document Type: Article

References (49)

1. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
2. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30 (Suppl 5): F24-F33.
3. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-88.
4. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35.
5. de Sanjosé S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
6. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59.
7. Bernard E, Pons-Salort M, Favre M, et al. Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies. BMC Infect Dis 2013; 13: 373.
8. Munoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
9. Berkhof J, Bulkmans NW, Bleeker MC, et al. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006; 15: 1268-73.
10. Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011; 103: 1387-96.
11. Matsumoto K, Oki A, Furuta R, et al. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011; 128: 2898-910.
12. Naucler P, Ryd W, Tornberg S, et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007; 97: 129-32.
13. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
14. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1398-409.
15. Wheeler CM, Hunt WC, Schiffman M, et al. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006; 194: 1291-9.
16. Wheeler CM, Hunt WC, Cuzick J, et al. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States. Int J Cancer 2014; 135: 624-34.
17. Castle PE, Schiffman M, Scott DR, et al. Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1311-4.
18. Gravitt PE, Kovacic MB, Herrero R, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007; 121: 2787-93.
19. Hesselink AT, Berkhof J, Heideman DA, et al. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. Int J Cancer 2009; 124: 381-6.
20. Monnier-Benoit S, Dalstein V, Riethmuller D, et al. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006; 35: 270-7.
21. van Duin M, Snijders PJ, Schrijnemakers HF, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002; 98: 590-5.
22. Xi LF, Kiviat NB, Galloway DA, et al. Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis 2008; 198: 324-31.
23. Xi LF, Hughes JP, Castle PE, et al. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis 2011; 203: 1425-33.
24. Sundstrom K, Ploner A, Dahlstrom LA, et al. Prospective study of HPV16 viral load and risk of in situ and invasive squamous cervical cancer. Cancer Epidemiol Biomarkers Prev 2013; 22: 150-8.
25. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 2189-93.
26. Moberg M, Gustavsson I, Wilander E, et al. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92: 891-4.
27. Xi LF, Koutsky LA, Castle PE, et al. Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst 2009; 101: 153-61.
28. Kjaer SK, Munk C, Junge J, et al. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 2014; 25: 179-89.
29. Thomsen LT, Frederiksen K, Munk C, et al. High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or Cancer. Obstet Gynecol 2014; 123: 57-64.
30. Danish National Board of Health. Screening against cervical cancer-recommendations [in Danish]. Copenhagen (Denmark): Danish National Board of Health; 2007.
31. Danish National Board of Health. Screening against cervical cancer-recommendations [in Danish]. Copenhagen (Denmark): Danish National Board of Health; 2012.
32. Danish Quality Assurance Database for Cervical Cancer Screening. Annual Report 2012 [in Danish]. Copenhagen (Denmark): Danish Quality Assurance Database for Cervical Cancer Screening; 2012. Available at https://www.sundhed.dk/content/cms/80/1880-dkls-%C3%A5rsrapport-2012.pdf (accessed 12-Aug-2014).
33. Bjerregaard B, Larsen OB,. The Danish pathology register. Scand J Public Health 2011; 39 (7 Suppl): 72-4.
34. Pedersen CB,. The Danish Civil Registration System. Scand J Public Health 2011; 39 (7 Suppl): 22-5.
35. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens, Part B: biological agents. Lancet Oncol 2009; 10: 321-2.
36. Turnbull BW,. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B 1976; 38: 290-5.
37. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003; 12: 477-84.
38. Iftner T, Villa LL,. Human papillomavirus technologies. J Natl Cancer Inst Monogr 2003; 31: 80-8.
39. Castle PE, Glass AG, Rush BB, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 2012; 30: 3044-50.
40. Barken SS, Rebolj M, Andersen ES, et al. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 2012; 130: 2438-44.
41. Moscicki AB, Schiffman M, Kjaer S, Villa LL,. Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24 (Suppl 3): S3/42-S3/51.
42. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9.
43. Combes JD, Guan P, Franceschi S, et al. Judging the carcinogenicity of rare human papillomavirus types. Int J Cancer 2015; 136: 740-2.
44. Schiffman M, Clifford G, Buonaguro FM,. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
45. Dijkstra M, van Niekirk D, Rijkaart DC, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen positive women? A POBASCAM trial sub study. Cancer Epidemiol Biomarkers Prev 2014; 23: 55-63.
46. Castle PE, Stoler MH, Wright TC Jr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-90.
47. Barzon L, Militello V, Pagni S, et al. Comparison of INNO-LiPA genotyping extra and hybrid capture 2 assays for detection of carcinogenic human papillomavirus genotypes. J Clin Virol 2012; 55: 256-61.
48. Naryshkin S, Austin RM,. Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening. Drug Healthc Patient Saf 2012; 4: 167-72.
49. Depuydt CE, Criel AM, Benoy IH, et al. Changes in type-specific human papillomavirus load predict progression to cervical cancer. J Cell Mol Med 2012; 16: 3096-104.